



Revance Therapeutics  
Investor Relations Department  
7555 Gateway Boulevard  
Newark, CA 94560  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: RVNC

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 23.75                      |
| Trade Time:   | 4:00 PM ET<br>Aug 16, 2017 |
| Change:       | 0.25  (+1.064%)            |
| Day Range     | 23.50 - 23.95              |
| 52-Week Range | 12.35 - 28.30              |
| Volume        | 80,956                     |


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which, when combined with active drug molecules, may help address current unmet needs.

Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthe... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Aug 3, 2017*  
[Revance Releases Second Quarter 2017 Results](#)
- Aug 2, 2017*  
[Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics](#)
- Aug 1, 2017*  
[Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics](#)
- Jul 24, 2017*  
[Revance Therapeutics to Release Second Quarter 2017 Financial Results Thursday, August 3, 2017](#)
- Jun 15, 2017*  
[Positive BELMONT Phase 2 Trial Results Published in Dermatologic Surgery](#)

## Financials [\[ View all \]](#)

- [Second Quarter Financial Results](#)  
*Feb 28, 2017*  
[Annual Report \(10-K\)](#)
- Mar 24, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Aug 4, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 9, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 4, 2016*  
[Quarterly Report \(10-Q\)](#)